Open

Evaluating Combinations of Medications After Stem Cell Transplant to Prevent Graft versus Host Disease and Infections

The purpose of this study is to look at combinations of medicines given after a stem cell transplant and see how well the combinations work to prevent graft versus host disease and infection.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will meet with the study team to see if you are eligible for the study. This includes an exam, labs, and testing. If you are eligible and in the first part of the study, you will receive your transplant and will be treated with a set combination of medicines to see if they can prevent graft versus host disease and infection. If you are eligible and in the second part of the study, you will receive your transplant and be randomized to receive a combination of medicines to see if they can prevent graft versus host disease and infection. Both parts of the study will include returning to clinic for up to 1 year after transplant for exams, labs, testing, and questionnaires.

Incentives

You will be reimbursed $20 for each study survey completed.

In-person visits:
18 visits

Total length of participation:
1 year

Looking for Specific Volunteers

Able to participate:

Diagnosis of AML, ALL, CML, MDS, CLL, CMML, MDP/MPN, or MF
Available Mis-Matched Unrelated Donor for transplant

Not eligible if:

HLA-matched related or 8/8 high-resolution matched unrelated donor available
You have had a prior allogeneic transplant
You have had an autologous transplant within the past 3 months
You have uncontrolled bacterial, viral, or fungal infection at the time of the transplant preparative regimen

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Janell Markey
janell_markey@med.unc.edu

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Katarzyna Jamieson
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Other Cancers, Leukemia, Lymphoma)
Transplant

IRB Number

25-1453

ClinicalTrials.gov

NCT06859424

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.